Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Valeant

Shire Basingstoke

Shire finally bags EU approval for rare disease drug Natpar

Becomes first licenced treatment for hypoparathyroidism in Europe

- PMLiVE

Japanese pharma pulls no punches with post-Brexit UK

Firm want reassurance from the UK on its future in science and innovation

Brexit: the facts (and the alternative facts)

How Brexit affects pharma

- PMLiVE

Brexit: Implications for the pharma industry

From patents to the EMA, data protection to clinical trials, there's a lot that should be a concern

Can UK pharma rise to the post-Brexit challenge?

Our dominant and thriving industry is one we should be proud of

- PMLiVE

Boehringer Ingelheim calls for “strong and united” Europe

Simone Menne highlights the EU's achievements, and her firm's contribution

- PMLiVE

Connecting the dots

What happens ‘here’ impacts what happens ‘there’

- PMLiVE

Walmsley steps up to chief executive role at GSK

The firm's first female CEO, she takes over from Sir Andrew Witty

- PMLiVE

UK pharma strikes optimistic note as Brexit process begins

Says life science industry is accustomed to ‘uncertainty’ and can thrive in a post-EU Britain

- PMLiVE

Brexit begins as UK PM signs letter triggering Article 50

Theresa May sets wheels in motion as Britain awaits EU response

National Institute for Health and Care Excellence NICE logo

NICE knocks-back Shire’s pancreatic cancer drug Onivyde

Final guidance rules it's not a cost-effective use of NHS resources

UK flag

ABPI delivers wish-list to Hammond ahead of spring budget

Pharma industry has three key requests

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links